A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer - Wikidata - awgldk - TriplyDB

A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer

A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer

http://www.wikidata.org/entity/Q33402374

about

Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer.Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer.A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.

P2860

Q33416894-6237B226-D12F-4B6A-813C-69AD6ACCE749 Q33418889-390B081D-8C16-40D4-8872-6B6913454C2F Q35429986-E6DE5D31-5F87-4D23-B9C5-90FFE412DF80 Q37582596-46F207C4-76AB-4750-A712-E04508BBEFD3

P2860

A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer

http://www.wikidata.org/entity/Q33402374

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

A Phase II Trial of Gemcitabin ...... ith Advanced Pancreatic Cancer

@ast

A Phase II Trial of Gemcitabin ...... ith Advanced Pancreatic Cancer

@en

type

label

A Phase II Trial of Gemcitabin ...... ith Advanced Pancreatic Cancer

@ast

A Phase II Trial of Gemcitabin ...... ith Advanced Pancreatic Cancer

@en

prefLabel

A Phase II Trial of Gemcitabin ...... ith Advanced Pancreatic Cancer

@ast

A Phase II Trial of Gemcitabin ...... ith Advanced Pancreatic Cancer

@en

P1433

Q33402374-8441930C-BDF6-4773-8777-282A20F418FC

P1476

Q33402374-216451D8-E168-4BF8-B522-0722A5BF0CFC

P2093

Q33402374-2E9BCEE4-97C3-44A9-A68F-BC6EDBB53FEE

Q33402374-588A3F73-C22D-401D-B121-844EBC8323F3

Q33402374-A05719CB-0D40-4140-A45F-4B7E3604B3DC

Q33402374-C4687FA7-BE05-41E1-94E5-2CF3892ADD09

Q33402374-E5020A95-E7C4-448C-BAD7-9EE7F41FE9F2

P2860

Q33402374-00B4FD14-FDAA-43EB-A9E0-908F8C42C6D5

Q33402374-1BC5A72E-59B3-4271-A1F7-62A1C99D0A95

Q33402374-35E504BB-9655-4F37-B456-CCB995C546F7

Q33402374-3F8F66EE-C0AD-467C-AB9C-3E05DB950614

Q33402374-6D4BABD2-31B8-45C2-8E89-D10BBCF4E691

Q33402374-7E31498B-931F-4344-99C9-BA8B3CC14E1E

Q33402374-8A62B468-108A-425F-9641-312309BEE442

Q33402374-931BA8C1-C001-4E99-AFC3-D836F075786C

Q33402374-955CB951-AB6A-4DF4-9EC3-E03DDB267578

Q33402374-9CDEF2F8-0972-4630-927F-A589D419DD1A

P304

Q33402374-160EB567-84CF-4923-9974-BAC163775F91

P31

Q33402374-36A90366-9DA8-4530-9A2F-5C7F85BF43C8

P356

Q33402374-1A7E2226-FB2F-4EAF-955A-62B65B4AF393

P433

Q33402374-501E843B-51E7-4F72-89B0-9F0300964B71

P478

Q33402374-F35BBD41-1805-49D6-9E43-2AF9D7EA641C

P577

Q33402374-5D8AA07B-951F-4946-8DBB-87A06E90AF12

P5875

Q33402374-16278246-049A-4E25-B702-20908D4BF2DB

P698

Q33402374-FE9882D2-0B22-4228-84F7-60EBFB1AF8CB

P921

Q33402374-431E4F0D-6CC8-45F9-992B-684620AD3F72

P932

Q33402374-D5C896B1-E9A0-40DF-9A07-7D0DF719FF05

P356

CRT.2012.44.2.127

P1433

Cancer Research and Treatment

P1476

A Phase II Trial of Gemcitabin ...... ith Advanced Pancreatic Cancer

@en

P2093

Chul Won Choi

http://www.w3.org/2001/XMLSchema#string

Jae Hong Seo

http://www.w3.org/2001/XMLSchema#string

Jong Gwon Choi

http://www.w3.org/2001/XMLSchema#string

Jun Suk Kim

http://www.w3.org/2001/XMLSchema#string

Sang Cheul Oh

http://www.w3.org/2001/XMLSchema#string

P2860

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

P304

127-132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4143/CRT.2012.44.2.127

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229157468

http://www.w3.org/2001/XMLSchema#string

P698

22802751

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3394862

http://www.w3.org/2001/XMLSchema#string